Enabling drug adherence through closed loop monitoring & communication

• US 20070172424A1
• Filed: 01/25/2007
• Published: 07/26/2007
• Est. Priority Date: 01/26/2006
• Status: Abandoned Application

• Current Assignee: Mark Costin Roser
• Original Assignee: Mark Costin Roser
• Inventors: Roser, Mark Costin
• Application Number:
  US11/698,642
• Publication Number:
  US 20070172424A1
• Time in Patent Office: Days
• US Class Current: 424/9.100
• CPC Class Codes: A61B 5/14546 for measuring analytes not otherwise provided for, e.g. ions, cytochromes
• CPC Class Codes: A61B 5/1455 using optical sensors, e.g. spectral photometrical oximeters
• CPC Class Codes: A61B 5/14555 specially adapted for the eye fundus
• CPC Class Codes: A61B 5/16 Devices for psychotechnics using teaching or educational appliances G09B1/00 - G09B7/00; Testing reaction times ; Devices for evaluating the psychological state
• CPC Class Codes: A61B 5/165 Evaluating the state of mind, e.g. depression, anxiety
• CPC Class Codes: G16H 10/20 for electronic clinical trials or questionnaires
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients
• CPC Class Codes: G16H 50/50 for simulation or modelling of medical disorders
• CPC Class Codes: G16H 70/40 relating to drugs, e.g. their side effects or intended usage

Abstract

A method is described for measuring the blood concentration of a medicament through the introduction of a tracer compound. The measurement of the blood concentration of the tracer will yield a result that will enable a prediction of the blood concentration of the medicament. The method further describes ways to utilize the results for monitoring adherence to the medicament and modifying behavior to help patients boost compliance.

Claims

1. A method of monitoring pharmaceutical adherence of a patient, comprising the steps of administering a medicament to the patient, acquiring data associated with administration of the medicament;

transmitting the data associated with said administration to an interactive communication device; and

displaying the data, wherein the display allows a determination of the pharmaceutical adherence of the patient to the medicament.

2. The method of claim 1, wherein the step of administration comprises administering a medicament having at least one active drug compound and at least one tracer compound and wherein the at least one tracer compound is capable of being detected by the interactive communication device.

3. The method of claim 1, further comprising the step of allowing the interactive communication device to transmit the data to a network server, wherein said server integrates the data into a medicament concentration model of the patient.

4. The method of claim 2, wherein the step of transmitting to an interactive communication device comprises a device having at least one sensor capable of detecting at least one tracer compound in a bodily fluid of the patient.

5. The method of claim 4, wherein the bodily fluid is selected from the group consisting of breath, saliva, and blood.

6. The method of claim 1, wherein the step of acquiring the data associated with administration of the medicament comprises acquiring data selected from the group consisting of physiological data, psychological data and behavioral data.

7. A method of creating an interaction between a patient and a medicament concentration model of a medicament administered to the patient, comprising the steps of:

acquiring data associated with administration of the medicament to the patient with an interactive communication device, wherein said device is communicatively coupled to a network server; and

allowing the network server to integrate the data into a drug concentration model of the medicament.

8. The method of claim 7, wherein the step of acquiring the data further comprises acquiring at least a portion of the data from the patient using an interactive sequence of questions through the interactive communication device so as to elicit at least one response from the patient.

9. The method of claim 8, wherein said step of acquiring the data comprises acquiring an interactive sequence of questions selected from the group consisting of questions associated with the patient'"'"'s behavior, questions associated with the patients'"'"' psychology, and questions associated with the patient'"'"'s physiology.

10. The method of claim 7, wherein the step of acquiring the data comprises acquiring data sufficient to predict a pharmacokinetic response of the patient to the medicament.

11. The method of claim 10, wherein the medicament administered to the patient comprises at least one active drug compound and at least one tracer compound.

12. The method of claim 11, wherein the step of acquiring data with an interactive communication device further comprises said acquiring data with said device that has at least one sensor for detecting at least one tracer compound in a bodily fluid of the patient.

13. The method of claim 12, wherein the step of allowing the server to integrate the data further comprises the steps of taking at least one sensor measurement of said at least one tracer compound and predicting at least one concentration of tracer compound in a fluid of the patient.

14. The method of claim 12, wherein the step of allowing the server to integrate the data further comprises the steps of taking at least one sensor measurement of said at least one tracer compound and predicting at least one concentration of active drug compound in a fluid of the patient.

15. The method of claim 10, the step of integrating data comprises utilizing at least one pre-existing pharmacokinetic model of said at least one active drug compound.

16. The method of claim 10, further comprising incorporating data sufficient to predict a pharmacokinetic response of the patient to the medicament into a behavior-modification system as a means to assist the user to maintain the defined medicament protocol.

17. The method of claim 10, further comprising incorporating data sufficient to predict a pharmacokinetic response of the patient to the medicament into a clinical trial management process to enables elimination of at least one user that is not properly following the defined medicament protocol.